Answers are grounded in this paper and cite their sources.
Mutant hematopoietic progenitor cells (HPC) may expand under high-dose melphalan- and lenalidomide-based regimens and give rise to hematologic second primary malignancies (SPM) in multiple myeloma. To determine whether genetic screening of mutant HPCs may facilitate individualized treatment to minimize the risk of SPMs, we sequenced a myeloid gene panel in 555 longitudinal CD34+ samples from 348 patients with multiple myeloma treated with lenalidomide-containing regimens and found that 23% carried mutant HPCs at diagnosis, which was associated with higher tumor burden and altered myelo-erythropoiesis, although not with inferior survival nor the development of SPMs. There was considerable fluctuation of mutant HPCs, particularly during maintenance, including the frequency of TP53 mutations increasing from 1% at diagnosis to 7% after treatment. Whereas these findings could speculate on the interest of monitoring mutant HPCs during maintenance for the potential identification of patients at greater risk of developing SPMs, overall, our study does not support the genetic screening for clonal hematopoiesis (CH) in multiple myeloma. Significance: SPMs that develop in patients with multiple myeloma have a deleterious impact on survival. Patients with CH may be at risk of developing SPMs, which could potentially be avoided through individualized treatment. However, our results suggest that screening for CH at diagnosis has limited utility.
No takes yet. Share an insight, caveat, or question.
Guerrero et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: